Developing new treatments for diabetes using 12-lipoxygenase inhibitors.
Official title: Development of 12-Lipoxygenase Inhibitors for diabetes treatment.
Funded at VA Northern California Health Care Sys · NIH-11186202 · Data updated 2026-11-12
This study is looking at a special enzyme that can make diabetes worse, especially in veterans who have had COVID-19, and it's testing a new treatment that might help improve insulin function and prevent diabetes from getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Northern California Health Care Sys NIH-funded |
| Lab location | 1 site (Mather, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| NIH project number | 1I21BX007163-01 |
| Project ID | NIH-11186202 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults, particularly veterans, who have been diagnosed with diabetes or are at risk of developing it.
✕Less likely to help
Patients who do not have diabetes or are under 21 years old may not benefit from this research.
What this research studies
This research focuses on developing inhibitors for the enzyme 12-lipoxygenase, which is linked to diabetes complications. The study aims to understand how this enzyme affects pancreatic beta cells and contributes to diabetes progression, particularly in veterans who have experienced COVID-19. By using advanced screening techniques, researchers have identified a promising inhibitor that could potentially improve insulin signaling and prevent the onset of diabetes. The research will involve laboratory experiments and may lead to new therapeutic options for managing diabetes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of diabetes and its complications.
How similar studies have gone: Previous research has shown that targeting 12-lipoxygenase can improve insulin signaling in animal models, indicating potential for success in human applications.
Where this research is happening
-
VA Northern California Health Care Sys
Mather, United States Active
Researchers
- Principal investigator: Nadler, Jerry L. — VA Northern California Health Care Sys
- Study coordinator: Nadler, Jerry L.
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.